Alexander Cumbo, president and chief executive officer of Solid Biosciences (NASDAQ: SLDB), sold 16,644 shares of the company's common stock on February 18, 2026, for about $96,923. The sales were completed at a weighted average price of $5.8233 per share, with the individual transaction prices spanning from $5.23 to $6.14.
The company’s stock is trading at $5.92, which the reporting notes is close to its InvestingPro Fair Value estimate. This level of trading comes amid a recent 2.63% decline in the share price over the prior week.
The disposition of shares was carried out to cover withholding taxes associated with the vesting of previously granted Restricted Stock Units. In a related move, Cumbo exercised 30,031 Restricted Stock Units on February 13, converting those units into common stock.
On the balance sheet front, Solid Biosciences is reported to have a market capitalization of $460 million and holds more cash than it carries in debt. The company is preparing to report earnings on March 6, a date described as just 15 days away from the transaction date.
InvestingPro analysis is cited as providing further detail on the company’s financial position, noting that additional metrics such as the financial health score and cash burn rate are available in its Pro Research Report for the biotech stock.
Beyond the insider sale, Solid Biosciences has disclosed several clinical and regulatory developments:
- The company said it reached alignment with the U.S. Food and Drug Administration on the Phase 3 clinical trial design for SGT-003, a candidate for Duchenne muscular dystrophy. The agreed design will be a randomized, double-blind, placebo-controlled study for the IMPACT DUCHENNE trial.
- Solid reported having dosed 33 participants in the Phase 1/2 INSPIRE DUCHENNE trial, and stated that the therapy has been generally well tolerated in that study.
- The FDA granted Orphan Drug designation to SGT-212, an investigational gene therapy targeting Friedreich’s ataxia, and the first participant has been dosed in the Phase 1b FALCON trial for that program.
- On the analyst front, Citizens reiterated a Market Outperform rating for Solid Biosciences and maintained a $15.00 price target following the FDA alignment on the Phase 3 trial.
Taken together, the insider transaction and recent corporate disclosures present a mix of near-term corporate finance activity and ongoing progress across the company’s clinical and regulatory programs.
For investors seeking valuation context, the article notes a Fair Value calculator that employs a blend of 17 industry valuation models. That tool is described as a way to compare the current stock price against a range of model-based estimates.
Readers should be aware that additional company-specific financial metrics are available through InvestingPro’s Pro Research Report, which reportedly details the company’s cash burn rate and financial health score.